- Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529
- This is the company's fourth of five patents to be granted, following China, Japan and Europe, with only Australia remaining
- The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion)
Read the Full Article on The Market Herald here
Recce Pharmaceuticals (ASX:RCE) granted US patent
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.5¢ |
Change
-0.025(3.79%) |
Mkt cap ! $134.6M | |||
| Open | High | Low | Value | Volume |
| 66.0¢ | 66.0¢ | 63.5¢ | $21.44K | 33.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1550 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 5084 | 3 |
View Market Depth
| Last trade - 11.18am 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
-0.025 ( 0.77 %) |
||||
| Open | High | Low | Volume | ||
| 65.5¢ | 66.0¢ | 64.5¢ | 11306 | ||
| Last updated 11.13am 01/05/2024 ? | |||||
| RCE (ASX) Chart |